Aprepitant Capsules 125 mg/80 mg (Apretero) – Oncology Export Supplier

Aprepitant capsules 125 mg/80 mg are prescription-only oral oncology medicines formulated for use within regulated cancer care and hospital treatment protocols. Marketed under the brand name Apretero, this product contains Aprepitant, a selective neurokinin-1 (NK1) receptor antagonist. Aprepitant capsules 125 mg/80 mg are manufactured for institutional healthcare supply and are offered strictly for international export to licensed pharmaceutical distributors, hospitals, and oncology treatment centers. AmeriDrugs does not supply this product for retail or direct-to-patient sales.

Active Ingredient

• Aprepitant IP – 125 mg and 80 mg capsules (combination pack)
  Aprepitant is a centrally acting substance that blocks NK1 receptors and is used under approved oncology supportive-care frameworks.

Therapeutic Use

From an informational and regulatory perspective, Aprepitant capsules 125 mg/80 mg are used in approved oncology supportive-care settings related to chemotherapy-associated treatment protocols, as authorized by health authorities in the importing country. This information is provided solely for product identification and international trade clarity. AmeriDrugs does not provide medical advice, treatment schedules, or patient-level guidance for Aprepitant capsules 125 mg/80 mg.

Dosage Form

• Oral solid dosage form

• Hard gelatin capsules

• Supplied as a combination pack suitable for hospital and institutional pharmacy dispensing

• Administration decisions are determined exclusively by qualified oncology professionals in accordance with local regulations

Quality & Manufacturing Standards

Aprepitant capsules 125 mg/80 mg (Apretero) are manufactured in GMP-compliant facilities operating under validated pharmaceutical quality management systems. Manufacturing processes include raw material qualification, in-process controls, and finished product testing to ensure identity, strength, purity, and consistency aligned with international export standards for Aprepitant capsules 125 mg/80 mg.

Packaging Information

• Combination pack containing 125 mg and 80 mg capsules

• Pharmaceutical-grade blister packaging

• Secure secondary packaging designed for international transport

• Labeling compliant with prescription oncology medicine regulations

Target Buyers

This product is intended exclusively for supply to:

• Licensed pharmaceutical importers and distributors

• Hospitals and oncology treatment centers

• Government and private cancer care institutions

• Authorized healthcare procurement agencies

It is not intended for retail pharmacies, online consumer sales, or direct patient distribution.

Regulatory & Compliance Note

Aprepitant capsules 125 mg/80 mg (Apretero) are prescription-only oncology medicines. Importation, distribution, and use must comply with the pharmaceutical laws, drug authority approvals, and oncology regulations of the destination country. Buyers are responsible for ensuring regulatory compliance within their jurisdiction. AmeriDrugs operates solely as an export-focused pharmaceutical supplier and does not promote Aprepitant capsules 125 mg/80 mg for self-medication or non-regulated use.